Portfolio News
Sofinnova Capital
Avantium nominates Kees Verhaar as Chairman Supervisory Board
Avantium nominates Kees Verhaar as Chairman Supervisory Board
Avantium N.V., (Euronext Amsterdam and Brussels: AVTX) (“Avantium” or “the Company”) a leading chemical technology company and forerunner in renewable chemistry, announces that today it has published its convocation of the Extraordinary General Meeting of shareholders (EGM) to be held at Avantium’s headquarters, Zekeringstraat 29, Amsterdam, The Netherlands on 30 November 2017 at 10.00 am CET. On the agenda is the appointment of Mr. Kees Verhaar as a new member to Avantium’s Supervisory Board.
Avantium’s Supervisory Board has nominated Kees Verhaar, who will join the Supervisory Board for a term of four years, subject to approval by shareholders at the EGM. He will succeed Mr. Jan van der Eijk, who had temporarily resumed his role as Chairman of the Supervisory Board of Avantium. Mr. Jan van der Eijk will resign with effect as of immediately after the EGM of 30 November 2017. He will continue in his role as Chairman of the Supervisory Board of Synvina, the Joint Venture of Avantium and BASF.
Once approved by the shareholders as a Supervisory Board member, Kees Verhaar will be appointed as Chairman of the Supervisory Board. His appointment will be effective immediately after the EGM of 30 November 2017.
Kees Verhaar’s experience as CEO of Arizona Chemicals, the world leading wood-based chemicals company and his 30-year track record in the chemical industry, which includes extensive collaboration with sophisticated financial investors are very valuable to support Avantium in building a winning renewable chemistry company. Kees Verhaar is currently chairman of the advisory board of three business units of Ten Cate, an international advanced materials company.
The convocation, agenda and explanatory notes for the EGM together with the resume of Mr. Kees Verhaar are published on the Company’s corporate website.
This is a public announcement by Avantium N.V. pursuant to section 17 paragraph 1 of the European Market Abuse Regulation (596/2014).
About Avantium
Avantium is a leading chemical technology company and a forerunner in renewable chemistry. Together with its partners around the world, Avantium develops efficient processes and sustainable products made from biobased materials. Avantium offers a breeding ground for revolutionary renewable chemistry solutions from invention to commercially viable production processes.
One of Avantium’s success stories is YXY technology, with which it created PEF: a completely new, high-quality plastic made from plant-based industrial sugars. Since October 2016 all YXY activities have been transferred to Synvina, the joint venture of Avantium and BASF.
Avantium is also working on a host of other groundbreaking projects such as the Zambezi process; a biorefinery technology to produce sugars for the production of chemicals and fuels from non-food materials. The proprietary process is highly feedstock-flexible allowing use of forestry residues (e.g. woodchips), corn stover, bagasse and produces a high purity 2G glucose product and lignin for energy and other applications. Avantium also provides advanced catalysis research services and systems to the leading chemical and petrochemical companies.
Avantium shares are listed on Euronext Amsterdam and Euronext Brussels (symbol: AVTX), its offices and headquarters are based in Amsterdam, the Netherlands. Over 120 highly skilled colleagues representing 20 nationalities, Avantium fosters a dynamic and enthusiastic workplace that is constantly seeking new ways to improve and expand the impact of advanced catalytic research & technology.
MEDIA CONTACT
For more information:
Dominique Levant, Marketing & Communications Officer
T: +31 20 586 01 32 - E: dominique.levant@avantium.com
or visit our website www.avantium.com.
Related News
Moon Surgical appoints Chris Toth as Independent Board Member ahead of commercial acceleration
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. join forces, building the next era of best-and first-in-class ophthalmic medicines
Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
ProQR Therapeutics announces $8.1 million in new funding from Rett Syndrome Research Trust to expand RNA editing collaboration
ProQR appoints Peter A. Beal, PhD, as Chief ADAR Scientist